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Background and Aim
In Germany, the discharge medication 
is usually reported to the general 
practitioner (GP) by an inital short 
report (SR) /notification (handed over 
to the patient) and later by a more 
detailed discharge letter (DL) of the 
hospital.
Material and Method
We asked N=536 GPs (from Frankfurt/
Main and Luebeck) after the typical 
report format of their patients 
discharge medication by the local 
hospitals. The questionnaire asked for 
26 items covering (1) the designation 
of the medication (brand name, generic 
name) in SR and DL, (2) further 
specifications e.g. possibilities of 
generic substitution or supervision of 
sensible medications, (3) reasons why 
GPs do not follow the hospitals 
recommendations and (4) possibilities 
for an improvement in the medication-
related communication between GP and 
hospitals.
Results
39% GPs responded sufficiently to the 
questionnaire. The majority of the GPs 
(82%) quoted that in the SR only brand 
names are given (often or ever) and 
neither the generic name or any further 
information on generic substitution is 
available (seldom or never). 65% of the 
responders quoted that even in the DL 
only brand names are given. Only 41% 
of the responders quoted that further 
treatment relevant specifications are 
given (often or ever). 95% responded 
that new medications or change of 
custom medication is seldom or never 
explained in the DL and GP were not 
explicitly informed about relevant medication changes. 58% of the 
responders quoted economic reasons 
for re-adjustment of the discharge 
medication e.g. by generic substitution. 
The majority of responders (83%) are 
favouring (useful or very useful) a pre-
discharge information (e.g. via fax) 
about the medication and 54% a hot-
line to some relevant person in the 
hospital when treatment problems 
emerge. 67% of the responders quoted 
in favour of regular meetings between 
GPs and hospital doctors regarding 
actual pharmacotherapy.
Conclusion
In conclusion, our survey pointed to 
marked deficiencies in reporting the 
discharge medication to GPs.
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